The estimated Net Worth of Steven C Quay is at least $13.2 Milion dollars as of 9 March 2016. Steven Quay owns over 15,000 units of Atossa Therapeutics Inc stock worth over $7,336,824 and over the last 12 years he sold ATOS stock worth over $41,120. In addition, he makes $5,807,920 as Chairman of the Board, President oraz Chief Executive Officer at Atossa Therapeutics Inc.
Sign up
Steven Quay ATOS stock SEC Form 4 insiders trading
Steven has made over 4 trades of the Atossa Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of ATOS stock worth $5,550 on 9 March 2016.
The largest trade he's ever made was buying 50,000 units of Atossa Therapeutics Inc stock on 19 January 2016 worth over $10,000. On average, Steven trades about 4,848 units every 49 days since 2013. As of 9 March 2016 he still owns at least 4,826,858 units of Atossa Therapeutics Inc stock.
You can see the complete history of Steven Quay stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Steven Quay biography
Dr. Steven C. Quay M.D. Ph.D. serves as Chairman of the Board, President, Chief Executive Officer of the Company. Dr. Quay is certified in Anatomic Pathology with the American Board of Pathology, completed both an internship and residency in anatomic pathology at Massachusetts General Hospital, a Harvard Medical School teaching hospital, and is a former faculty member of the Department of Pathology, Stanford University School of Medicine. Dr. Quay is a named inventor on 87 U.S. patents, 134 pending U.S. patent applications, and is named inventor on patents covering seven pharmaceutical products that have been approved by the U.S. Food and Drug Administration. Dr. Quay received an M.D. in 1977 and a Ph.D. in 1975 from the University of Michigan. He received his B.A. degree in biology, chemistry and mathematics from Western Michigan University in 1971. He was selected to serve on the Company’s Board of Directors because of his role as a founder of the Company, as well as his qualifications as a physician and the principal researcher overseeing the clinical and regulatory development of the Company’s pharmaceutical programs.
What is the salary of Steven Quay?
As the Chairman of the Board, President oraz Chief Executive Officer of Atossa Therapeutics Inc, the total compensation of Steven Quay at Atossa Therapeutics Inc is $5,807,920. There are no executives at Atossa Therapeutics Inc getting paid more.
How old is Steven Quay?
Steven Quay is 69, he's been the Chairman of the Board, President oraz Chief Executive Officer of Atossa Therapeutics Inc since . There are 2 older and 6 younger executives at Atossa Therapeutics Inc. The oldest executive at Atossa Therapeutics Inc is Stephen Galli, 73, who is the Independent Director.
What's Steven Quay's mailing address?
Steven's mailing address filed with the SEC is C/O ATOSSA THERAPEUTICS, INC.,, 107 SPRING STREET, SEATTLE, WA, 98104.
Insiders trading at Atossa Therapeutics Inc
Over the last 12 years, insiders at Atossa Therapeutics Inc have traded over $114,740 worth of Atossa Therapeutics Inc stock and bought 274,300 units worth $204,285 . The most active insiders traders include Gregory L Weaver, Steven C Quay oraz Shu Chih Chen. On average, Atossa Therapeutics Inc executives and independent directors trade stock every 205 days with the average trade being worth of $38,260. The most recent stock trade was executed by Jonathan Finn on 10 April 2024, trading 25,000 units of ATOS stock currently worth $44,250.
What does Atossa Therapeutics Inc do?
atossa therapeutics, inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the united states. the company's lead program is the development of endoxifen, an active metabolite of tamoxifen which is in phase ii studies to treat and prevent breast cancer. it is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and chimeric antigen receptor t-cell therapies, directly to the site of breast cancer. the company was formerly known as atossa genetics inc. and changed its name to atossa therapeutics, inc. in january 2020. atossa therapeutics, inc. was founded in 2009 and is headquartered in seattle, washington.
What does Atossa Therapeutics Inc's logo look like?
Complete history of Steven Quay stock trades at Atossa Therapeutics Inc
Atossa Therapeutics Inc executives and stock owners
Atossa Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Steven Quay,
Chairman of the Board, President, Chief Executive Officer -
Kyle Guse,
Chief Financial Officer, General Counsel, Secretary -
Dr. Steven C. Quay,
Chairman, CEO & Pres -
Kyle Guse CPA, Esq., CPA,
CFO, Gen. Counsel & Sec. -
Shu-Chih Chen,
Director -
Gregory Weaver,
Independent Director -
Scott Gordon,
IR Contact Officer -
Richard Steinhart,
Independent Director -
H. Lawrence Remmel,
Independent Director -
Stephen Galli,
Independent Director -
Janet Rose Rea MSPH, RAC,
Sr. VP of Regulatory, Quality & Clinical Affairs -
Delly Behen P.H.R.,
VP of Admin. & HR -
Heather Rees,
VP of Fin. & Accounting -
Janet Rose Rea,
Sr. VP of Regulatory, Quality & Clinical Affairs -
Scott Youmans,
Chief Operating Officer -
Heather Rees,
SVP, Finance and Accounting -
Jonathan Finn,
-
Tessa Cigler,
-
Christopher S. Destro,
Sr. VP, Sales and Marketing -
John Barnhart,
Director -
John E Sawyer,
See Remarks -
Peter J. Carbonaro,
Sr. Vice President, Operations -
Ben R Chen,
Sr. VP of Glob. Reg. Affairs -
Alexander D Cross,
Director